News | Lung Imaging | July 17, 2020

Focusing on lung cancer screening subjects less likely to remain in a program -- those with negative low-dose CT exams and those who still smoke — improves that program's cost-effectiveness, while maximizing societal benefits

"Our study demonstrates that a real-world lung cancer screening can perform similar to randomized controlled trials in regard to important performance metrics," the UPenn authors of this AJR article concluded. Image courtesy of American Journal of Roentgenology (AJR)

"Our study demonstrates that a real-world lung cancer screening can perform similar to randomized controlled trials in regard to important performance metrics," the UPenn authors of this AJR article concluded. Image courtesy of American Journal of Roentgenology (AJR)


July 17, 2020 — An online first accepted manuscript published in ARRS' American Journal of Roentgenology (AJR) finds that focusing on lung cancer screening (LCS) subjects less likely to remain in the program — those with negative low-dose computed tomography (LDCT) exams and those who still smoke — can improve that program's cost-effectiveness and maximize its societal benefits.

For people with a long history of smoking, LDCT LCS has been shown to decrease mortality; however, adherence to an LCS program remains significantly lower than in randomized controlled trials.

To assess real-world LDCT LCS performance and factors predictive of adherence to recommendations, three radiologists from the University of Pennsylvania's Perelman School of Medicine retrospectively recorded patient demographics, smoking history and behavior changes, Lung-RADS category, PPV and NPV, and adherence to screening recommendations for 260 subjects returning for follow-up LDCT from 2014 to 2019.

Forty-three subjects (16.5%) had positive scans, of which 28/260 (10.8%) were Lung-RADS category 3, 8/260 (3.1%) were 4A, 6/260 (2.3%) were 4B, and 2/260 (0.8%) were 4X.

Four subjects were diagnosed with cancer: 3 lung, 1 metastatic melanoma.

Meanwhile, 143/260 (55%) subjects were current smokers at baseline, and 121/260 (46.5%) were current smokers during the last round of LCS.

Both LCS sensitivity and NPV were 100%, while specificity was 84.8% and PPV was 9.3%.

Overall adherence was 43%, though it increased progressively the higher the Lung-RADS category. Additionally, adherence was higher in former vs. current smokers (50% vs. 36.2%; p = 0.002). Ultimately, there were only two significant independent predictors of adherence: having smoked previously and a positive (? 3) Lung-RADS category.

"Our study demonstrates that a real-world LCS can perform similar to randomized controlled trials in regard to important performance metrics," concluded first author Eduardo J. Mortani Barbosa, Jr.

Acknowledging that an economic incentive, such as an insurance premium reduction, could improve LCS adherence, Barbosa, Jr. et al. added that multimodal communication (i.e., face-to-face discussions with radiologists, letters from referring providers, reminders via electronic health records) should be investigated and incentivized.

"Such communications should emphasize that a negative LCS exam does not confer immunity to future lung cancer development," the authors of this AJR article noted, "and that continued participation in LCS, combined with smoking cessation, is essential to accrue the maximum benefits of mortality reduction amongst persons with substantial smoking history."

For more information: www.arrs.org


Related Content

News | FDA

March 1, 2024 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S ...

Time March 01, 2024
arrow
News | Artificial Intelligence

February 29, 2024 — AIxSCAN, Inc., a Sunnyvale, CA-based developer of a next generation artificial intelligence (AI) ...

Time February 29, 2024
arrow
News | Artificial Intelligence

February 27, 2024 — Median Technologies announced that the Company will be participating and speaking at the premier ...

Time February 27, 2024
arrow
News | X-Ray

February 26, 2024 — AIxSCAN, Inc. began clinical trials in late 2023. The AIxSCAN, Inc. team is very pleased with the ...

Time February 26, 2024
arrow
News | Artificial Intelligence

February 26, 2024 — DeepHealth, Inc., one of the leading providers in healthcare radiology informatics, has today ...

Time February 26, 2024
arrow
News | Quality Assurance (QA)

February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...

Time February 12, 2024
arrow
Videos | RSNA

At RSNA23, Imaging Technology News (ITN) spoke with Bhvita Jani, principal analyst at Signify Research, about ...

Time February 07, 2024
arrow
News | Interventional Radiology

February 6, 2024 — RenovoRx, Inc., a clinical-stage biopharmaceutical company developing novel precision oncology ...

Time February 06, 2024
arrow
News | ACR

February 6, 2024 — An update to the CT Colonography Reporting and Data System (C-RADS) has been published Jan. 30 in the ...

Time February 06, 2024
arrow
News | Treatment Planning

February 2, 2024 — RaySearch Laboratories announced that the number of radiotherapy centers that have chosen RayStation ...

Time February 02, 2024
arrow
Subscribe Now